NASDAQ:ENTX Entera Bio Q3 2025 Earnings Report $2.14 -0.16 (-6.96%) Closing price 04:00 PM EasternExtended Trading$2.11 -0.03 (-1.40%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Entera Bio EPS ResultsActual EPSN/AConsensus EPS -$0.09Beat/MissN/AOne Year Ago EPSN/AEntera Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEntera Bio Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateFriday, November 7, 2025Conference Call Time7:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Entera Bio Earnings HeadlinesEntera Bio stock rises after positive Phase 2 bone density data4 hours ago | investing.comEntera Bio presents clinical data from EB613 Phase 2 trial4 hours ago | msn.comArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.October 23 at 2:00 AM | Banyan Hill Publishing (Ad)Entera Bio Reports Positive Phase 2 Results for Oral Anabolic Treatment EB613 at NAMS 2025, Paving Way for Global Phase 3 StudyOctober 23 at 9:11 AM | quiverquant.comQEntera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal WomenOctober 23 at 8:50 AM | globenewswire.comEntera Bio Ltd. to Present Phase 2 Clinical Data for EB613 at NAMS 2025 Annual MeetingOctober 16, 2025 | quiverquant.comQSee More Entera Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Entera Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entera Bio and other key companies, straight to your email. Email Address About Entera BioEntera Bio (NASDAQ:ENTX), Inc. is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations. The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis. EB613 entered Phase 1 clinical trials to assess safety, tolerability and pharmacokinetics in healthy volunteers. In parallel, Entera Bio is advancing EB612, an oral tumor necrosis factor (TNF) antagonist, toward early‐stage clinical development for inflammatory diseases such as rheumatoid arthritis and Crohn’s disease. Since its founding in 2010, Entera Bio has established operations in Newton, Massachusetts, and research facilities in Israel, positioning the company at the intersection of North American and international biopharmaceutical innovation. Its leadership team combines expertise in peptide chemistry, clinical development, regulatory affairs and commercial strategy. Entera Bio plans to collaborate with established pharmaceutical partners to support late‐stage clinical programs and the global commercialization of its oral peptide product candidates.View Entera Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla’s Earnings Review: Does the Juice Justify the Squeeze?Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings Signal Upcoming Earnings Sanofi (10/24/2025)ENI (10/24/2025)General Dynamics (10/24/2025)HCA Healthcare (10/24/2025)ICICI Bank (10/24/2025)Illinois Tool Works (10/24/2025)Coca Cola Femsa (10/24/2025)NatWest Group (10/24/2025)Procter & Gamble (10/24/2025)Cadence Design Systems (10/27/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
